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besity and type 2 diabetes consti-
tute major public health issues in
modern societies worldwide. Their
prevalence on a global scale is alarming,
and efforts to control their spread repre-
sent a priority of the public health agenda
(1). Obesity is clearly driving a parallel
epidemicofassociatedchronicdiseasesin
all age-groups, including type 2 diabetes,
hyperlipidemia, hypertension, athero-
sclerosis, obstructive sleep apnea, and
liver dysfunction. Considerable attention
is currently being focused on the conse-
quences of obesity in vulnerable popula-
tions at both ends of the age spectrum,
namely in youth and in the elderly.
Elderlypeople,deﬁnedasindividuals
65 years of age, comprise a substantial
and growing part of the population in de-
veloped countries. Current demographic
data in Western societies report that 12–
15% of the general population is over the
age of 65 years, and this proportion is
projected to reach 20–25% by the year
2030 (2). Moreover, in the last 2 decades,
the rate of obesity has risen dramatically
amongolderadults,independentlyofsex,
race, and educational level (3). This obe-
sity epidemic signiﬁcantly affects the
health status of the geriatric population,
since excess body weight in the elderly
also correlates strongly with chronic ill
health, poor quality of life, functional de-
cline, disability, and dependency (4).
Conversely, evidence suggests that
obesity in the elderly is probably not as-
sociatedwiththesamerisksasinyounger
individuals, while in certain aspects, can
even be protective (5). Furthermore, the
prevalence of underweight is higher
among older adults, who are also more
vulnerable to unintentional weight loss
either as a result of illness, or due to the
aging process itself.
Theobjectiveofthisarticleistoassess
the beneﬁts relative to risks of weight loss
that may be attained in the geriatric pop-
ulation, with special reference to the el-
derly diabetic patient.
WHAT IS AN APPROPRIATE
DEFINITION OF OBESITY IN
THE ELDERLY?— “Healthy” or “ideal”
body weight is the ultimate objective of
obesity treatment guidelines aiming to
mitigate obesity-related health risks and
improve quality of life (6). However, def-
initions of “healthy” body weight rely on
incidence rates of associated diseases and
on total mortality data, which vary across
the age spectrum. Currently, the criteria
appliedtodeﬁneobesityarebasedonBMI
values, calculated as measured body
weight (kg) divided by measured height
squared (m
2), which provide a gross eval-
uation of total body fat.
Deﬁning criteria of “healthy” weight
fortheelderlyposesachallengeinclinical
practice because of physiological changes
related to aging, primarily in body com-
position and stature. Indeed, although
body weight may remain stable, the pro-
portion of body fat increases with age,
whileadegreeofheightlossiscommonin
older adults (e.g., due to narrowed inter-
vertebral disc spaces, osteoporotic verte-
bral compressions, and kyphosis). Thus,
the accuracy of BMI as an indicator of ad-
iposity decreases with increasing age (7).
Radiographic evaluation of body fat
depots has been proposed as a more pre-
cise method to characterize obesity in the
elderly. However, implementing such
techniques in regular practice, as well as
measuring total body fat mass, is not re-
alistic; hence, anthropometric indexes of
fat distribution currently offer the most
practical method of evaluating obesity in
older adults. Waist circumference, mea-
sured in the horizontal plane midway be-
tween the superior iliac crest and the
lower margin of the last rib, has been
shown to positively correlate with ab-
dominal fat mass, providing a simple and
reliable assessment of obesity and central
adiposity (8). Waist circumference is an
independentriskfactorforcardiovascular
disease (CVD), and assessment of central
obesity holds greater prognostic value
than BMI alone (9). Waist circumference
cutoff points for the diagnosis of central
obesity are a matter of debate, and differ-
ent thresholds must be used based on sex
and ethnicity, parameters that signiﬁ-
cantly affect the associated metabolic risk
of central adiposity. According to the Na-
tional Heart, Lung, and Blood Institute
guidelines, women and men with waist
circumferences 88 cm and 102 cm, re-
spectively, are considered to be at high
riskforCVD.Thesecutoffpointsareused
in the criteria of the metabolic syndrome
by the National Cholesterol Education
Program Adult Treatment Panel III (10).
Themorerecentmetabolicsyndromedef-
inition by the International Diabetes Fed-
eration sets ethnicity speciﬁc criteria for
waistcircumferencetodeﬁnecentralobe-
sity in adults, with cutoff points equal to
80 and 94 cm for Caucasian women and
men, respectively (11). However, these
thresholds do not take age into account,
and further validation of their application
in the elderly is essential to deﬁne age-
speciﬁc action levels.
EFFECTS OF AGING ON
BODY COMPOSITION AND
FAT DISTRIBUTION— Age-related
physiological changes have a marked im-
pactonbodycomposition,inducingade-
cline in lean (muscle and bone) body
mass and total body water in parallel with
an increase in fat mass (12,13). Thus, al-
though excess weight gain may be absent
or limited in older adults, the underlying
increase of adiposity can be signiﬁcant.
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mately during the 5th or 6th decade of
life, with a later peak in women after
menopause,andremainsratherstablebe-
tween the ages of 65 and 70 years,
whereasaslowweightdeclinebeginsafter
the age of 70 years and continues for the
remainder of life (13).
This age-dependent weight loss in
later life with stable or increasing adipos-
ityisadditionallycharacterizedbyaredis-
tribution of the fat mass that favors
enhanced visceral and ectopic (e.g., intra-
muscular, hepatic) adipose tissue accu-
mulation. Longitudinal studies have
shown that there is a signiﬁcant mean in-
creaseinwaistcircumferencewithageper
year, which is of similar magnitude in all
age strata, indicating that older adults
continue to exhibit progressive increases
in waist circumference (14). These data
have been conﬁrmed by studies using ra-
diographic techniques to assess regional
fat distribution in young and older indi-
viduals. The results reported enhanced
visceralandectopicfatdepositionincom-
bination with loss of subcutaneous fat
mass (e.g., reduced subcutaneous gluteo-
femoral fat depots) in the elderly (15,16).
Thus, although subcutaneous fat in-
creases with rising BMI, it progressively
decreases with aging and, additionally,
intra-abdominalfataccumulationpersists
in old age even without total body weight
gain. Therefore, it seems that in the el-
derly, underweight and low lean body
massisbetterevaluatedbymeasurements
of BMI (low BMI more accurately reﬂects
the associated risk of underweight),
whereas obesity and adiposity is better
evaluated by measurements of waist cir-
cumference(increasedwaistcircumference
more accurately reﬂects the associated risk
of obesity) (17).
OBESITY AND RISK OF
DIABETES— Obesity, particularly of
long duration and of the visceral type, is
the cornerstone in type 2 diabetes patho-
genesis. Depending on ethnicity and sex,
50–90% of type 2 diabetic patients ex-
hibit BMI values 25 kg/m
2, with the
higher incidence rates reported in older
patients(18).Notably,therelativeriskfor
diabetesinadultsappearstoincreaseeven
at BMI values 25 kg/m
2 and rises expo-
nentially as BMI increases. The patho-
physiological pathways behind this
association are complex and progressive,
leading to development of insulin resis-
tanceandsecondaryimpairmentof-cell
function. Moreover, type 2 diabetic pa-
tients with excess body weight are at
particularly increased risk for CVD mor-
bidity and mortality, since additional
CVD risk factors (e.g., hypertension and
dyslipidemia) tend to cluster with obe-
sity, forming a constellation of metabolic
comorbidities, described as the metabolic
syndrome.
Adipose tissue accumulation, espe-
ciallyvisceral,inducesaspectrumofmet-
abolic and hormonal changes, which
progressively impair the insulin signal
transduction pathway and manifest as in-
creasing insulin resistance in adipose
tissue, liver, and skeletal muscle. Altered
adipokine production (e.g., increased tu-
mor necrosis factor- and decreased
adiponectin secretion) and increased in-
ﬂammatory load with expanding obesity
havebeenidentiﬁedaspathogeneticlinks
to type 2 diabetes (19). Notably, de-
creased insulin sensitivity at the cellular
level is also a natural consequence of
aging.
Impaired -cell function and insulin
secretion defects are also essential for the
development of type 2 diabetes and
progress gradually for years before the
clinical onset of the disease (19). In-
creased -cell mass is a crucial compen-
satory mechanism against insulin
resistance,withthepopulationofpancre-
atic -cells reﬂecting a dynamic balance
between neogenesis, proliferation, and
apoptotic processes in the islets of Lang-
erhans that are regulated in an age-
dependent manner. Genetic predisposition
and aging contribute to -cell dysfunction,
whichtogetherwithchronicglucotoxicand
lipotoxiceffectsoftheinsulin-resistantstate
in obesity lead to dysregulated glycemic
control and overt type 2 diabetes.
Anotherimportantconsiderationisthat
diabetestreatmentitselfmayalsocontribute
tofurtherweightgain.TheU.K.Prospective
Diabetes Study has clearly demonstrated
theweight-increasingeffectsofinsulinand
sulfonylureas in patients with type 2 dia-
betes over time (20), as indeed has been
shown for glitazones (21). Paradoxically,
weight gain in these diabetic patients has
been associated with reduction of the risk
of both micro- and macrovascular com-
plications. This paradoxical association
appearstodependonvariousparameters,
such as the level of achieved glycemic
control, as well as the degree and
distribution of weight gain. The balance
between treatment-induced weight in-
creases and associated clinical beneﬁts is
even more delicate in elderly diabetic pa-
tients, who generally represent a popula-
tion with multiple CVD risk factors.
WEIGHT LOSS AND
DIABETES PREVENTION— Effec-
tive treatment of obesity with sustained
weightlosscollectivelyimprovesthemet-
abolic proﬁle and decreases the risk for
related complications. Lifestyle modiﬁca-
tion, including dietary and physical activ-
ity interventions, must be the initial step
in the weight management plan and
should be emphatically encouraged.
Pharmacotherapy for tackling obesity
should also be initiated early, especially
whenlifestyleinterventionsfailtoachieve
or maintain weight loss, to prevent the
onset of metabolic diseases.
Prospectivestudieshavedocumented
that the degree and duration of weight
gain in adult life are powerful predictors
of type 2 diabetes and CVD, while even
moderate sustained weight loss may have
a signiﬁcant impact on metabolic risk re-
duction, diabetes prevention, and CVD
outcomes (Table 1) (22,23). Wanna-
methee and Shaper (24) studied a large
cohort of middle-aged men to examine
prospectively the effects of baseline BMI
Table 1—Potential beneﬁts and risks related
to weight loss in older adults
Health beneﬁts of weight loss
Reduced risk for developing type 2
diabetes in subjects with impaired
glucose tolerance
Reduced cardiovascular risk—improved
glycemic, lipid, and blood pressure
control
Potentially reduced mortality risk from
CVD (with intentional weight loss in
obese patients)
Improved respiratory function and
obstructive sleep apnea control
Improved functional capacity and reduced
musculoskeletal comorbidities
Improved depressive symptoms, sense of
well-being, and quality of life
Health risks of weight loss
Potentially increased mortality risk (with
unintentional weight loss and less with
intentional weight loss)
Loss of muscle mass (sarcopenia) if not
combined with regular exercise
Loss of bone mineral density,
osteoporosis, and increased risk for
fractures
Increased risk of speciﬁc protein and
vitamin deﬁciencies
Increased risk of gallstone attacks (in rapid
weight loss)
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comes and the effects of documented
weight change later in the follow-up pe-
riod. Their studies conﬁrmed the role of
excessweight,especiallyoflongduration,
in the development of type 2 diabetes,
showing that the associated diabetes risk
increased progressively and signiﬁcantly
with rising levels of initial BMI and with
the duration of overweight and obesity.
Notably,inmiddle-agedmen,weightloss
appears to be associated with signiﬁcant
reduction in risk for type 2 diabetes, but
not in CVD, indicating that severity and
duration of obesity seems to limit the car-
diovascular beneﬁts of weight reduction
in older men (25).
Agrowingbodyofevidencefromsev-
eral intervention (dietary/lifestyle, phar-
macological, and surgical) weight
management studies supports the notion
that the onset of type 2 diabetes can be
substantially delayed, and even pre-
vented, by weight reduction in high-risk
patients with impaired glucose tolerance.
IntheFinnishDiabetesPreventionStudy,
which recruited overweight middle-aged
volunteers with impaired glucose toler-
ance, intensive lifestyle (dietary, exercise,
and behavioral) intervention signiﬁcantly
reduced by 58% the risk for developing
type 2 diabetes, compared with the con-
trol group (26). Furthermore, this effect
was at least partly preserved during the
long-term follow-up period. Notably, the
intervention was most effective among
the oldest (age over 61 years) individuals,
with a relative risk reduction of 64%,
compared with that in the control group
(27). The Diabetes Prevention Program
Research Group also conducted a large
randomized clinical trial in the U.S., de-
signed to evaluate the safety and efﬁcacy
of interventions aiming at preventing or
delaying development of type 2 diabetes
in adults at high risk for the disease (28).
Diabetes incidence in this study was also
reduced signiﬁcantly by 58%, with inten-
sive lifestyle intervention compared with
placebo. Lifestyle intervention was highly
effective in all study subgroups, being
similarly effective in older and younger
participants,whereastheadvantageofthe
lifestyle intervention over metformin was
higher in older individuals.
Initiation of pharmacotherapy for
weight management, in addition to life-
style interventions, may help achieve and
maintain even greater body weight loss,
and hence can further contribute in re-
ducing the risk for type 2 diabetes in
obese individuals. The Xenical in the Pre-
vention of Diabetes in Obese Subjects
(XENDOS)studyevaluatedorlistatversus
placebo plus lifestyle intervention in
obese patients with either normal glucose
tolerance or impaired glucose tolerance.
After a 4-year treatment period, the addi-
tion of orlistat to lifestyle changes pro-
duced greater weight loss in this obese
population, compared with lifestyle
changes alone. Furthermore, orlistat
treatment resulted in a risk reduction of
37% for development of type 2 diabetes,
an effect that was signiﬁcant in patients
with baseline impaired glucose tolerance
(29).
Bariatric surgery represents the next
step in weight management strategies af-
ter failure to achieve or maintain weight
loss with lifestyle interventions and anti-
obesity drugs. Following the proposed
guidelines, surgical interventions have
been shown to effectively treat obesity,
leadingtopreventionorremissionofobe-
sity-related complications (30). The
Swedish Obese Subjects (SOS) study, a
large prospective study, evaluated the
long-term effects of bariatric surgery for
morbid obesity. In this cohort, the surgi-
cally treated group had signiﬁcantly
greater weight reduction and markedly
lower 2- and 10-year incidence rates of
type 2 diabetes than the conventionally
treated control group. These results high-
light the primary preventive effect of
weight loss on type 2 diabetes, which
seems to persist for up to 10 years after
surgery (31).
ACHIEVING WEIGHT
CONTROL IN TYPE 2
DIABETES: LIFESTYLE AND
DRUG INTERVENTIONS— Weight
losshasawell-establishedroleindiabetes
prevention, and its recommendation is
common practice in the care of type 2
diabetic patients. However, the extent of
long-termbeneﬁtsfromobesitytreatment
after the clinical onset of type 2 diabetes
are less precisely documented, since data
from large randomized intervention trials
directly evaluating this objective are lim-
ited (32,33). Evidence in support of this
widely accepted notion is mainly derived
from cross-sectional and retrospective
studies. In 1990, Lean et al. (34) pub-
lished a retrospective study, reporting
that weight loss improves life expectancy
in established type 2 diabetes based on
data from medical records of deceased
type 2 diabetic patients who were fol-
lowed up in an Aberdeen diabetic clinic
and had survived for at least 1 year after
diagnosis. The mean age at diagnosis was
65 years (range 57–75), and the authors
concluded that the analysis of survival
data in these patients provided, for the
ﬁrsttime,evidencethatweightlossforthe
treatment of diabetes improves life ex-
pectancy. However, precise interpreta-
tionofsuchretrospectivenonrandomized
studies is difﬁcult, highlighting the need
forbetterandlargeprospectivestudieson
the association between weight loss and
survival in type 2 diabetes, especially in
the elderly. The ongoing Look AHEAD
trial, assessing the impact of weight loss
and medical nutrition therapy on long-
term cardiovascular mortality and mor-
bidity in patients 45–75 years old with
type 2 diabetes and BMI 25 kg/m
2,i s
expected to provide valuable data to sup-
port evidence-based recommendations
(35).
Although intentional weight loss
seemstohaveapositiveeffectfordiabetes
outcomes, achieving optimum glycemic
control in combination with weight loss
may prove difﬁcult in the care of type 2
diabetic patients, especially in the long
term. Weight-promoting effects of many
essentially used glucose-lowering regi-
mens (e.g., sulfonylureas, glinides, glita-
zones, insulin, and their combinations)
constitute an obvious obstacle for effec-
tive weight control and represent a con-
founding factor regarding the beneﬁts of
weightlossindiabetesmanagementtrials.
Untilrecently,metforminofferedtheonly
reliable treatment option not favoring
weight gain. At present, novel classes of
antidiabetic agents have become avail-
able, namely incretin mimetics (e.g., ex-
enatide) and dipeptidyl peptidase-4
(DPP4) inhibitors (gliptins, e.g., sitaglip-
tin, vildagliptin), which improve glyce-
mic control and protect -cell function,
while at the same time promote weight
reduction (36). Adopting regimens favor-
ing weight control should be generally
preferred for the management of type 2
diabetes,butnotattheexpenseofhypergly-
cemia.Notably,type2diabeticpatientswill
lose less weight than nondiabetic patients
for any given intervention, particularly el-
derly diabetic subjects who also exhibit a
progressiveage-relateddeclineinmetabolic
rates.
Several options for weight loss inter-
ventions in diabetes could be applied in
clinical practice (37). Lifestyle modiﬁca-
tions should rely on small but permanent
changes to the daily living of the patient.
Ahealthydiet,includinga500–600kcal/
day calorie deﬁcit, is recommended with
Kyrou and Tsigos
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ally apply techniques (e.g., motivational
interviewing) to achieve successful be-
haviormodiﬁcations.Reinforcementaim-
ing at realistic increases in physical
activity is also essential, since regular ex-
ercise reduces abdominal fat and protects
lean body mass, which is a crucial param-
eter for the elderly. This approach im-
proves insulin sensitivity, plasma lipids,
and blood pressure proﬁles; contributes
to enhanced general ﬁtness and well-
being; and additionally helps long-term
weight maintenance (Table 1).
Improvements in measures of glyce-
mic control (e.g., in A1C) with weight
reduction appear to be generally propor-
tional to the amount of weight lost. Thus,
combined interventions with anti-obesity
pharmacotherapy may be particularly ad-
vantageous for type 2 diabetic patients,
since they promote greater weight loss
and encourage long-term lifestyle
changes. Anti-obesity drugs should be
considered as part of a comprehensive
treatment strategy. Pharmacotherapy for
weight loss in obese patients with an
obesity-related comorbidity (e.g., type 2
diabetes, hypertension) is currently rec-
ommended for BMI 27 kg/m
2 (6). The
efﬁcacy of pharmacotherapy should be
evaluated after an initial 3-month period
and subsequently the treatment should
be either continued if the achieved
weight loss is satisfactory (3% in type
2 diabetic patients) or discontinued in
nonresponders.
Existing data for the licensed anti-
obesity drugs (orlistat, sibutramine, and
rimonabant in the European Union only)
provide limited proof to support an evi-
dence-based choice for the individual pa-
tient. All three agents produce moderate
andbroadlysimilarabsoluteandplacebo-
subtracted weight loss effects. Currently,
therapeutic choices are predominantly
determined by excluding drugs for which
speciﬁc contraindications are present
(e.g., orlistat: chronic malabsorption
syndrome and cholestasis; sibutramine:
inadequately controlled hypertension
145/90mmHg,psychiatricillness,con-
comitant use of monoamine oxidase in-
hibitors or of other centrally acting drugs
fortreatmentofpsychiatricdisorders,his-
tory of coronary artery disease; rimon-
abant: history of major depressive illness
and/or ongoing antidepressive treatment,
severe hepatic or renal impairment).
Orlistat is a nonsystemic gastric and
pancreatic lipase inhibitor that inhibits
the absorption of dietary fat by approxi-
mately one-third and, in combination
with appropriate diet, additionally re-
ducesthedailyenergyintakeby100–300
kcal. Orlistat has been evaluated in stud-
ies with type 2 diabetic patients (38,39).
The addition of orlistat generally resulted
in greater weight loss than placebo, al-
though the degree of achieved weight re-
duction was less than that documented in
studies with nondiabetic patients (40). A
modest placebo-subtracted weight loss of
2–3 kg was noted; however, almost
twice as many patients achieved a weight
loss 5% of body weight. This effect was
associated with signiﬁcant improvements
in glycemic control, blood pressure, and
lipid proﬁles.
Sibutramineisacentrallyactingagent
that enhances satiety and decreases hun-
ger by inhibiting norepinephrine and se-
rotonin reuptake, whereas it may also
slightly increase thermogenesis. Sibutra-
minetreatmenthasalsobeenevaluatedin
type 2 diabetic patients treated with diet
alone, metformin, or sulfonylureas (39–
42). The placebo-subtracted weight loss
in these studies was in the range of 4–5
kg,withapproximatelytwotothreetimes
as many patients losing 5% of body
weight compared with placebo. This ef-
fect was associated with improved lipid
proﬁles and glycemic control, the latter
particularly in responders with greater
weight loss. However, small increases in
blood pressure and pulse rate were also
noted, which in addition to the contrain-
dication in patients having uncontrolled
hypertension and established cardiovas-
cular disease, may limit the application of
sibutramine in the diabetic population,
especially among the elderly.
Rimonabant, a selective antagonist of
the type 1 cannabinoid receptors, has
been shown to induce signiﬁcant weight
loss in patients with type 2 diabetes and
central obesity, while additionally im-
proving glycemic, lipid, and blood pres-
sure control (43). The average placebo-
subtracted weight loss was 4k gi nt h e
rimonabant in obesity diabetes trial (44).
The most important adverse effect of
rimonabantwasanincreasedincidenceof
psychiatric disorders (e.g., depression,
anxiety, irritability) (40).
METABOLIC SURGERY: ARE
THERE BENEFITS IN THE
ELDERLY?— Surgical approaches to
obesity management are becoming in-
creasingly sophisticated, and most of the
procedures are now performed laparo-
scopicallywithmarkedlyimprovedsafety
andefﬁcacy.Atthemoment,bariatricsur-
gery offers the most effective treatment
optionformorbidobesityregardinglong-
termsustainedweightloss.Surgicalinter-
ventions in morbidly obese patients have
been shown to signiﬁcantly improve both
comorbidityandquality-of-lifestatusand
to decrease the overall long-term mortal-
ity (30,31).
Currently applied surgical proce-
dures are categorized into purely restric-
tive(adjustablegastricbandingandsleeve
gastrectomy), gastric restrictive with
some malabsorption (Roux-en-Y gastric
bypass), and gastric restrictive with sub-
stantial intestinal malabsorption (bilio-
pancreatic diversion without or with
duodenal switch). Adjustable gastric
bandingandRoux-en-Ygastricbypassare
now the most common bariatric proce-
dures, with the former being relatively
safer. It must be stressed that multidisci-
plinary skills are needed to support surgi-
cal interventions for obesity, especially in
high-risk elderly patients. Thus, it is vital
that all patients are referred to specialized
units that are also able and willing to pro-
vide long-term follow-up.
Surgery should be considered for
patients with BMI levels 40.0 kg/m
2,
or with BMI in the 35.0–39.9 kg/m
2
rangeandatleastoneassociatedcomor-
bidity (e.g., type 2 diabetes, hyperten-
sion) that could be improved by weight
loss (30).
There is now consensus that bariatric
surgery should be considered for treat-
ment of type 2 diabetes in patients with
BMI 35 kg/m
2 who are inadequately
controlled by lifestyle interventions and
pharmacotherapy. Indeed, studies re-
porting on comorbidities after bariatric
surgery showed signiﬁcant improvement
or even resolution of type 2 diabetes, and
of coexisting metabolic syndrome mani-
festations (45). Beneﬁts of bariatric sur-
gery remain controversial in geriatric
populations, and currently there is no
consensus regarding the safety and efﬁ-
cacy of surgical weight management in-
terventions in this age-group. However,
the demand for such procedures in older
adults is rising because of the growing
prevalence of obesity in this age-group.
Several studies have reported that gastric
banding and gastric bypass procedures
can be performed safely in patients over
the age of 60 years. The achieved weight
loss in elderly patients seems less satisfac-
tory compared with younger adults, but
still the majority of these patients show
Obesity in the elderly
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HEALTH RISKS
ASSOCIATED WITH WEIGHT
LOSS IN THE ELDERLY— Current
health trends and increasing life expect-
ancy in Western societies are expected to
inevitably result in progressively escalat-
ing obesity rates among the older popula-
tion. However, the ultimate health
consequences of this phenomenon still
remain somewhat unspeciﬁed; thus, it is
no surprise that the topic of obesity and
aging is one of growing discussion and
intensive new research.
Extrapolating from established detri-
mental effects of excess adiposity in
young and middle-aged adults, one
would conclude that signiﬁcant increases
in obesity-related morbidity and mortal-
ity should be expected in the elderly
obese population. Surprisingly, most ep-
idemiological data, mainly from cross-
sectional, but also from longitudinal,
studies, argue in favor of beneﬁcial or
neutral,ratherthandetrimental,effectsof
increased BMI on life expectancy after the
age of 65 years. Furthermore, weight loss
intheelderlyappearstoholdvariousrisks
related mainly to loss of lean body mass
and potential nutritional deﬁciencies (Ta-
ble 1) (4,5,47).
Weight reduction inevitably incorpo-
rateslossofmuscleandbonemass,which
appears to be proportionately similar in
young and old adults. However, the im-
pact of this effect on body composition
can be signiﬁcantly greater in the elderly
because of the additional age-dependent
gradual decline in lean body mass. Fur-
thermore, data in this age-group support
the notion that signiﬁcantly more muscle
and bone mass is lost with weight loss
compared with lean mass obtained with
weight gain of a similar degree (48). Such
body composition changes in the aging
individualmayhaveseriousimplications,
particularly if weight is periodically lost
and regained, since they could accelerate
sarcopenia and result in sarcopenic obe-
sity and frailty.
Dietary restriction in older adults
holds greater risk of inadequate macro-
andmicronutrientintakethatcouldcause
speciﬁc protein and vitamin deﬁciencies
(47). Thus, dietary interventions in this
age-group should address nutritional
needs relating to age-associated physio-
logic and metabolic changes, as well as to
potential drug-associated nutritional de-
ﬁciencies. Balanced protein intake is cru-
cialinolderindividuals,especiallyduring
calorie restriction, to maintain levels that
help preserve muscle and bone mass, and
at the same time, do not increase the risk
of renal impairment (e.g., excessive pro-
tein intake in older adults is associated
with glomerular sclerosis). Administra-
tion of speciﬁc vitamins and minerals,
such as calcium and vitamin D, has been
advocated in the elderly, since they po-
tentially protect against bone mineral
density decline and reduce the risk of
bone fractures. Other micronutrients at
risk of deﬁcient intake in the elderly in-
clude vitamin B12, iron, and zinc, which
may also require supplementation.
It becomes evident that when weight
loss is considered essential in elderly
obesepatients,weightmanagementinter-
ventions should also aim at minimizing
the associated lean body mass loss. Phys-
ical activity is crucial for this goal, by in-
creasing energy expenditure and offering
multiple beneﬁts beyond weight reduc-
tion (6). Data from studies in older obese
patients suggest that regular exercise pro-
tects against muscle and bone mass loss
during dietary restriction.
To date, several questions remain un-
resolved regarding beneﬁts and risks of
weight loss in the elderly. To provide ev-
idence-basedanswers,well-designedran-
domized intervention studies are needed
in large groups of older overweight and
obese subjects, which could evaluate the
long-termsafetyandefﬁcacyofcontrolled
weight management interventions.
SUMMARY— Obesity and weight
loss in the geriatric population exhibit
rather distinct characteristics that can be
brieﬂy summarized in the following key
points:
1. Body weight increases approximately
up to the 5th or 6th decade of life and
then progressively declines as part of
the aging process. However, the prev-
alence of obesity is increasing in the
elderly population, and, indeed, late-
life obesity constitutes a threat to pub-
lic health status in developed societies.
2. Indexes of centralized fat distribution,
primarily waist circumference, appear
to have greater prognostic value than
BMI for characterizing obesity and as-
sociatedhealthrisksintheelderly.BMI
alone reﬂects more accurately the asso-
ciated risk of underweight in this
age-group.
3. Weight gain, and particularly visceral fat
redistribution associated with aging,
seems to further contribute to increased
risk for metabolic comorbidities, func-
tional decline, disability, and earlier
mortality.
4. Intentional weight loss may have ben-
eﬁcial effects in the elderly. Even small
but sustained weight loss (not exceed-
ing 10% of initial body weight) can
prove beneﬁcial in older obese adults,
while weight cycling appears to hold
additional risks. Diabetes risk and gly-
cemic control do improve with weight
reduction in this age-group, whether
this is achieved by lifestyle interven-
tion, pharmacotherapy, or surgery.
5. Weight loss interventions should be
cautious and individualized in older
patients to limit lean body mass loss
and avoid nutritional deﬁciencies.
Risk-beneﬁt analysis is crucial in deci-
sions of weight management in the el-
derly, and expected beneﬁts must be
assessed against potential detrimental
effects of weight loss. Establishing the
long-term beneﬁts and/or risks of such
interventions after the age of 65 years
requires further study.
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